Drug intelligence / Profile preview

MUC-1+CD19 CAR-T cells

Development stage: Unknown
Lead developer: PersonGen BioTherapeutics
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies

Overview

MUC-1+CD19 CAR-T cells is an investigational, target-defined dual-antigen chimeric antigen receptor T-cell therapy described in the Chinese Clinical Trial Register for advanced pancreatic cancer. The product name denotes CAR-engineered T cells intended to recognize **mucin-1** and **CD19**, triggering antigen-dependent T-cell cytotoxicity against cells bearing either targeted antigen. ChiCTR1900022608 was registered on April 18, 2019 by The Fifth Hospital Affiliated to Zhongshan University, with Innovative Cellular Therapeutics listed as the applicant institution. ([chictr.org.cn](https://www.chictr.org.cn/showprojEN.html?proj=38180))

Other names: (MUC-1+CD19) targeted Chimeric Antigen Receptor T CellsMUC-1+CD19 CAR-T cellsMUC-1+CD19 CART

Targets

Tn-MUC1 (Mucin 1 (Tn-glycoform))CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on MUC-1+CD19 CAR-T cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MUC-1+CD19 CAR-T cells.

Explore the full profile